Daiichi Sankyo shuts down a German R&D shop

Daiichi Sankyo is closing up its German research outpost, shuttering the former U3 Pharma as it consolidates its global R&D presence. U3, located in Martinsried, employs about 40 people with a focus on antibody treatments for cancer. The group's work will transfer to Daiichi's biologics research outpost in Tokyo, the company said. The move comes as the Japanese drugmaker cuts costs around the globe, this year announcing plans to lay off about 1,200 U.S. workers as it shifts its focus from primary care drugs to specialty pharma. Daiichi acquired U3 in 2008 for about $235 million in cash. More

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.